Análisis en la investigación de los nutrientes neuroprotectores, en el paciente con enfermedad de Parkinson (EP).

La enfermedad de Parkinson (EP), es uno de los trastornos neurodegenerativos más prevalentes a nivel mundial, afectando aproximadamente a 10 millones de personas. (1) La investigación sobre nutrientes neuroprotectores, ha emergido como un área prometedora para el desarrollo de intervenciones dietéti...

Full description

Autores:: Vásquez Sánchez, María Paula
Trujillo Tobón, Sarah

Tipo de recurso:

Fecha de publicación:: 2024

Institución:: Universidad Libre

Repositorio:: RIU - Repositorio Institucional UniLibre

Idioma:

id	RULIBRE2_87d840e9825a1cb71571c9094b6804a3
oai_identifier_str	oai:repository.unilibre.edu.co:10901/30379
network_acronym_str	RULIBRE2
network_name_str	RIU - Repositorio Institucional UniLibre
repository_id_str
dc.title.spa.fl_str_mv	Análisis en la investigación de los nutrientes neuroprotectores, en el paciente con enfermedad de Parkinson (EP).
dc.title.alternative.spa.fl_str_mv	Analysis in the investigation of neuroprotective nutrients in the Parkinson's disease patient
title	Análisis en la investigación de los nutrientes neuroprotectores, en el paciente con enfermedad de Parkinson (EP).
spellingShingle	Análisis en la investigación de los nutrientes neuroprotectores, en el paciente con enfermedad de Parkinson (EP). Enfermedad de Parkinson Nutrientes Neuroprotectores Antiinflamatorios Parkinson's disease Nutrients Neuroprotective Anti-inflammatory Agents
title_short	Análisis en la investigación de los nutrientes neuroprotectores, en el paciente con enfermedad de Parkinson (EP).
title_full	Análisis en la investigación de los nutrientes neuroprotectores, en el paciente con enfermedad de Parkinson (EP).
title_fullStr	Análisis en la investigación de los nutrientes neuroprotectores, en el paciente con enfermedad de Parkinson (EP).
title_full_unstemmed	Análisis en la investigación de los nutrientes neuroprotectores, en el paciente con enfermedad de Parkinson (EP).
title_sort	Análisis en la investigación de los nutrientes neuroprotectores, en el paciente con enfermedad de Parkinson (EP).
dc.creator.fl_str_mv	Vásquez Sánchez, María Paula Trujillo Tobón, Sarah
dc.contributor.advisor.none.fl_str_mv	Buritica, Hector Mario
dc.contributor.author.none.fl_str_mv	Vásquez Sánchez, María Paula Trujillo Tobón, Sarah
dc.subject.spa.fl_str_mv	Enfermedad de Parkinson Nutrientes Neuroprotectores Antiinflamatorios
topic	Enfermedad de Parkinson Nutrientes Neuroprotectores Antiinflamatorios Parkinson's disease Nutrients Neuroprotective Anti-inflammatory Agents
dc.subject.subjectenglish.spa.fl_str_mv	Parkinson's disease Nutrients Neuroprotective Anti-inflammatory Agents
description	La enfermedad de Parkinson (EP), es uno de los trastornos neurodegenerativos más prevalentes a nivel mundial, afectando aproximadamente a 10 millones de personas. (1) La investigación sobre nutrientes neuroprotectores, ha emergido como un área prometedora para el desarrollo de intervenciones dietéticas, que podrían modificar el curso de la enfermedad. El objetivo de esta revisión fue, analizar los avances recientes en la investigación sobre nutrientes neuroprotectores en la enfermedad de Parkinson. Evaluando el potencial neuroprotectora como estrategias terapéuticas complementarias, se realizó una revisión bibliográfica siguiendo las directrices PRISMA (Preferred Reporting Items For Systematic Reviews and Meta-Analyses) consultando las bases de datos electrónicas PubMed, Scielo, Scopus, Dialnet, Science Direct y Google académico. Se incluyó estudios científicos, revisiones sistemáticas, ensayos clínicos aleatorizados y estudios de cohorte que evaluaran específicamente nutrientes con factor neuroprotector en la enfermedad de Parkinson. La vitamina E, el ácido docosahexaenoico (DHA), la coenzima Q10, los polifenoles y flavonoides demostraron modular vías inflamatorias y disminución de la α-sinucleina demostrando resultados prometedores; la evidencia actual sugiere un papel prometedor de los nutrientes neuroprotectores en la enfermedad de Parkinson, aunque se requiere mayor investigación para traducir estos hallazgos en intervenciones clínicas efectivas se destacan determinadas estrategias nutricionales personalizadas así como la intervención dietoterapéutica considerando factores genéticos, ambientales y el estadio de la enfermedad.
publishDate	2024
dc.date.accessioned.none.fl_str_mv	2024-12-04T17:12:50Z
dc.date.available.none.fl_str_mv	2024-12-04T17:12:50Z
dc.date.created.none.fl_str_mv	2024-11-29
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
dc.type.local.spa.fl_str_mv	Tesis de Pregrado
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/bachelorThesis
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/10901/30379
url	https://hdl.handle.net/10901/30379
dc.relation.references.spa.fl_str_mv	Saavedra Moreno JS, Millán PA, Buriticá Henao OF. Introducción, epidemiología y diagnóstico de la enfermedad de Parkinson. Acta Neurológica Colombiana. 2019 Sep 1;35(3 Supl 1):2–10. Saavedra Moreno JS, Millán PA, Buriticá Henao OF. Introducción, epidemiología y diagnóstico de la enfermedad de Parkinson. Acta Neurológica Colombiana. 2019 Sep 1;35(3 Supl 1):2–10. Muentes Solorzano JM, Lucas Quijije JK, Menéndez Pin T del R, Cornejo Vera JV. Causas y efectos de los pacientes diagnosticados con el mal de Parkinson. RECIMUNDO. 2020 Oct 15;4(4):496–508. Ospina-García N. Trastornos del sueño y dolor en la enfermedad de Parkinson. Acta Neurológica Colombiana. 2019 Sep 1;35(3 Supl 1):63–8. Rodríguez-Carrillo JC, Ibarra M. Depresión y otros trastornos afectivos en la enfermedad de Parkinson. Acta Neurológica Colombiana. 2019 Sep 1;35(3 Supl 1):53–62. Erro R, Brigo F, Tamburin S, Zamboni M, Antonini A, Tinazzi M. Nutritional habits, risk, and progression of Parkinson disease. Vol. 265, Journal of Neurology. Dr. Dietrich Steinkopff Verlag GmbH and Co. KG; 2018. p. 12–23. María A, Periñán T, Directores T, Mir P, María Del Pilar Gómez R, Universidad G, et al. Estudio de factores genéticos y otros marcadores moleculares en la enfermedad de Parkinson Tesis Doctoral. Sienes Bailo P, Llorente Martín E, Calmarza P, Montolio Breva S, Bravo Gómez A, Pozo Giráldez A, et al. Implicación del estrés oxidativo en las enfermedades neurodegenerativas y posibles terapias antioxidantes. Advances in Laboratory Medicine. 2022 Dec 1;3(4):351–60. Tresserra MP, Pineda S. Nutrición y enfermedades neurodegenerativas [Internet]. 2020 [cited 2024 Nov 15]. Available from: https://openaccess.uoc.edu/bitstream/10609/150123/4/NutricionYEnfermedadesNeur odegenerativas.pdf Martínez-Boo N. The role of dietary habits in Parkinson’s disease signs and symptoms: a systematic review. Revista Cientifica de la Sociedad Espanola de Enfermeria Neurologica. 2021 Jul 1;54:30–7. Navajas J. Efectos de la Dieta Mediterránea en la enfermedad de Parkinson [Internet]. 2023 [cited 2024 Nov 15]. Available from: https://uvadoc.uva.es/bitstream/handle/10324/61311/TFG-M-N3094.pdf?sequence=1 Quezada Rivera RA, Bonilla Rodríguez FE, Benavides Romero MA, Peña Martínez SL. Alteraciones genéticas asociadas a enfermedad de Parkinson y Alzheimer: evolución y respuesta al tratamiento. Alerta, Revista científica del Instituto Nacional de Salud. 2024 Jan 25;7(1):79–87. Vallejo Zambrano CR, Jiménez Jiménez RA, Morán Rodríguez VE, Gómez Chumo ME, Del Valle Pilay MB, Palma Moreno NJ. Síndrome de Parkinson: Revisión bibliográfica y actualización. RECIMUNDO. 2020 Oct 15;4(4):270–81. Martínez Raull, Gasca C, Sánchez Á, Angel. Jose. Actualización en la enfermedad de Parkinson. 2020;363–79. Cófreces P, Ofman SD, Estay JA, Hermida PD. Enfermedad de Parkinson: una actualización bibliográfica de los aspectos psicosociales. Rev Fac Cienc Med Cordoba. 2022 Jun 6;79(2):181–7. Telarović S. Epidemiology of Parkinson’s Disease. Vol. 59, Archives of psychiatry research. Dr. Mladen Stojanovic University Hospital; 2023. p. 147–8. Estrada I, Martínez H. DIagnóstico y tratamiento de la enfermedad de Parkinson. 8:7. Miranda M, Kuljis R. Transtornos del sueño en las enfermedades neurodegenerativas. 2013 [cited 2024 Nov 15];452–62. Available from: https://www.elsevier.es/es-revista- revista-medica-clinica-las-condes-202-articulo-trastornos-del-sueno-enfermedades- neurodegenerativas- S0716864013701810#:~:text=Los%20trastornos%20del%20sue%C3%B1o%20son, por%20lo%20tanto%20no%20mitigado Gushiken G. RESONANCIA MAGNÉTICA PARA DIAGNÓSTICO PARKINSON EN ETAPA TEMPRANA. Universidad San Martin de Porras; 2021. Alvarez L, Sánchez C, AlvareZ E. SPECT en la enfermedad del Parkinson y otros trastornos del movimiento. Revista Mexicana de neurociencia. 2001;169–75. Zorro-Guío ÓF, Ardila-Martínez MA, Bedoya-Gómez Á, Restrepo HF, Mosquera- Sinisterra JE, Páez C, et al. Deep brain stimulation for Parkinson’s disease: experience, 17 benefits and limitations in a center in Latin America. Cirugia y Cirujanos (English Edition). 2024 May 1;92(3):362–8. Arbelo J, López J, Durán M, Linazasoro G. Guías diagnósticas y terpéuticas de la Sociedad Española de Neurologia [Internet]. 2016 [cited 2024 Nov 16]. Available from: https://www.sen.es/pdf/guias/Guia_oficial_de_practica_clinica_en_la_enfermedad_d e_Parkinson_2016.pdf Rodríguez-Violante M, Cervantes-Arriaga A. julio-septiembre 2014 \| 157 Fabián Dolores-Velasco, et al Arch Neurocien (Mex) INNN. Vol. 19, Arch Neurocien (Mex). 2014. Cabello González C, Trandafir PC. The study of health-related quality of life using PDQ39 in patients with Parkinson’s disease treated with advanced therapies. Revista Cientifica de la Sociedad Espanola de Enfermeria Neurologica. 2018 Jul 1;48:9–14. Bouça-Machado R, Fernandes A, Ranzato C, Beneby D, Nzwalo H, Ferreira JJ. Measurement tools to assess activities of daily living in patients with Parkinson’s disease: A systematic review. Vol. 16, Frontiers in Neuroscience. Frontiers Media S.A.; 2022. Garrido Robres JA, García Ballesteros JG, Martín Villuendas AB. Exploración neurológica y atención primaria. Bloque II: motilidad voluntaria, funciones corticales superiores y movimientos anómalos. Semergen. 2011 Oct;37(8):418–25. Berganzo K, Tijero B, González-Eizaguirre A, Somme J, Lezcano E, Gabilondo I, et al. Síntomas no motores y motores en la enfermedad de Parkinson y su relación con la calidad de vida y los distintos subgrupos clínicos. Neurologia. 2016 Nov 1;31(9):585– 91. Icer MA, Arslan N, Gezmen-Karadag M. Effects of vitamin e on neurodegenerative diseases: An update. Acta Neurobiol Exp (Wars). 2021;81(1):21–33. Chang MC, Kwak SG, Kwak S. Effect of dietary vitamins C and E on the risk of Parkinson’s disease: A meta-analysis. Clinical Nutrition. 2021 Jun 1;40(6):3922–30. Mantle D, Heaton RA, Hargreaves IP. Coenzyme Q10, Ageing and the Nervous System: An Overview. 2021; Available from: https://doi.org/10.3390/antiox11010002 Espino Y Sosa S, Reyes-Muñoz E, García-Jiménez G, Martínez-Ruiz A, Cristo- Aguirre MS, Adame-Pinacho R, et al. Impact of omega-3 fatty acid during pregnancy and risk reduction for preterm delivery. Gac Med Mex. 2020;156:S37–42. Van Duynhoven J, Vaughan EE, Jacobs DM, Kemperman RA, Van Velzen EJJ, Gross G, et al. Metabolic fate of polyphenols in the human superorganism. Proc Natl Acad Sci U S A. 2011 Mar 15;108(SUPPL. 1):4531–8. Khan Nova N, Sultana S, Akther R, Ahsan Habib M. Correlation of serum zinc and magnesium with reduced heart rate variability in male Parkinson’s disease patients. Available from: https://doi.org/10.3329/jbsp. Lloret A, Esteve D, Monllor P, Cervera-Ferri A, Lloret A. The effectiveness of vitamin E treatment in alzheimer’s disease. Vol. 20, International Journal of Molecular Sciences. MDPI AG; 2019. Stover PJ. Physiology of Folate and Vitamin B<SUB>12</SUB> in Health and Disease. Nutr Rev. 2006 Mar 23;62(6):3–12. Christine CW, Auinger P, Joslin A, Yelpaala Y, Green R. Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson’s Disease. Movement Disorders. 2018 May 1;33(5):762–70. Heo JH, Hyon-Lee, Lee KM. The possible role of antioxidant vitamin C in Alzheimer’s disease treatment and prevention. Vol. 28, American Journal of Alzheimer’s Disease and other Dementias. SAGE Publications Inc.; 2013. p. 120–5. Smith AD, Refsum H. Homocysteine, B Vitamins, and Cognitive Impairment. Vol. 36, Annual Review of Nutrition. Annual Reviews Inc.; 2016. p. 211–39. Gillies N, Cameron-Smith D, Pundir S, Wall CR, Milan AM. Exploring trajectories in dietary adequacy of the B vitamins folate, riboflavin, vitamins B 6 and B 12, with advancing older age: A systematic review. Vol. 126, British Journal of Nutrition. Cambridge University Press; 2021. p. 449–59. Salazar K, Jara N, Ramírez E, de Lima I, Smith-Ghigliotto J, Muñoz V, et al. Role of vitamin C and SVCT2 in neurogenesis. Vol. 17, Frontiers in Neuroscience. Frontiers Media SA; 2023. Jamali B, Entezari M, Babaei N, Hashemi M. The Evaluation of Vitamin E and TiO2 Nanoparticles Administration in Parkinson’s Rat Model. Cell J. 2023 Feb 1;25(2):102–9. Hao X, Li H, Li Q, Gao D, Wang X, Wu C, et al. Dietary vitamin E intake and risk of Parkinson’s disease: a cross-sectional study. Front Nutr. 2023;10. Taghizadeh M, Tamtaji OR, Dadgostar E, Daneshvar Kakhaki R, Bahmani F, Abolhassani J, et al. The effects of omega-3 fatty acids and vitamin E co- supplementation on clinical and metabolic status in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Neurochem Int. 2017 Sep 1;108:183–9. Olesen RH, Hyde TM, Kleinman JE, Smidt K, Rungby J, Larsen A. Obesity and age- related alterations in the gene expression of zinc-transporter proteins in the human brain. Transl Psychiatry. 2016;6(6). Sikora J, Ouagazzal AM. Synaptic zinc: An emerging player in Parkinson’s disease. Vol. 22, International Journal of Molecular Sciences. MDPI; 2021. Fan YG, Wu TY, Zhao LX, Jia RJ, Ren H, Hou WJ, et al. From zinc homeostasis to disease progression: Unveiling the neurodegenerative puzzle. Pharmacol Res. 2024 Jan 1;199:107039. Lee J, Park S, Jang W. Serum zinc deficiency could be associated with dementia conversion in Parkinson’s disease. Front Aging Neurosci. 2023;15. Vink Robert, Nechifor Mihai. Magnesium in the Central Nervous System. Cambridge University Press; 2012. Kirkland AE, Sarlo GL, Holton KF. The role of magnesium in neurological disorders. Vol. 10, Nutrients. MDPI AG; 2018. Yamanaka R, Shindo Y, Oka K. Magnesium is a key player in neuronal maturation and neuropathology. Int J Mol Sci. 2019 Jul 2;20(14). Huang J, May JM. Ascorbic acid protects SH-SY5Y neuroblastoma cells from apoptosis and death induced by β-amyloid. Brain Res. 2006 Jun 30;1097(1):52–8. Ascorbate-regulation-and-its-neuroprotective-role-. Ballaz S, Morales I, Rodríguez M, Obeso JA. Ascorbate prevents cell death from prolonged exposure to glutamate in an in vitro model of human dopaminergic neurons. J Neurosci Res. 2013 Dec;91(12):1609–17. Shults CW, Oakes D, Kieburtz K, Flint Beal ; M, Haas ; Richard, Juncos JL, et al. Effects of Coenzyme Q 10 in Early Parkinson Disease Evidence of Slowing of the Functional Decline. Cardoso HD, Santos Junior EF Dos, De Santana DF, Gonçalves-Pimentel C, Angelim MK, Isaac AR, et al. Omega-3 deficiency and neurodegeneration in the substantia nigra: Involvement of increased nitric oxide production and reduced BDNF expression. Biochimica et Biophysica Acta (BBA) - General Subjects. 2014 Jun 1;1840(6):1902–12. Valente M, Dentoni M, Bellizzi F, Kuris F, Gigli GL. Specialized Pro-Resolving Mediators in Neuroinflammation: Overview of Studies and Perspectives of Clinical Applications. Vol. 27, Molecules. MDPI; 2022. Yakunin E, Loeb V, Kisos H, Biala Y, Yehuda S, Yaari Y, et al. α-Synuclein neuropathology is controlled by nuclear hormone receptors and enhanced by docosahexaenoic acid in a mouse model for Parkinson’s disease. Brain Pathology. 2012 May;22(3):280–94. Zhang M, Wang S, Mao L, Leak RK, Shi Y, Zhang W, et al. Omega-3 fatty acids protect the brain against ischemic injury by activating Nrf2 and upregulating heme oxygenase 1. Journal of Neuroscience. 2014;34(5):1903–15. Bousquet M, Saint‐Pierre M, Julien C, Salem N, Cicchetti F, Calon F. Beneficial effects of dietary omega‐3 polyunsaturated fatty acid on toxin‐induced neuronal degeneration in an animal model of Parkinson’s disease. The FASEB Journal. 2008 Apr;22(4):1213–25. Nielsen SS, Franklin GM, Longstreth WT, Swanson PD, Checkoway H. Nicotine from edible Solanaceae and risk of Parkinson disease. Ann Neurol. 2013;74(3):472–7. Vauzour D, Rodriguez-Mateos A, Corona G, Oruna-Concha MJ, Spencer JPE. Polyphenols and human health: Prevention of disease and mechanisms of action. Vol. 2, Nutrients. MDPI AG; 2010. p. 1106–31. Williams RJ, Spencer JPE, Rice-Evans C. Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med. 2004 Apr 1;36(7):838–49. Singh NA, Mandal AKA, Khan ZA. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Vol. 15, Nutrition Journal. BioMed Central Ltd.; 2016. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, et al. ()- Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans [Internet]. 2006. Available from: www.pnas.orgcgidoi10.1073pnas.0510168103 Rendeiro C, Rhodes JS, Spencer JPE. The mechanisms of action of flavonoids in the brain: Direct versus indirect effects. Neurochem Int. 2015 Oct 1;89:126–39. Faria A, Mateus N, Calhau C. Flavonoid transport across blood-brain barrier: Implication for their direct neuroprotective actions. Nutrition and Aging. 2012;1(2):89–97. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by b vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PLoS One. 2010;5(9):1–10. McCarter SJ, Teigen LM, McCarter AR, Benarroch EE, St. Louis EK, Savica R. Low Vitamin B12 and Parkinson Disease: Potential Link to Reduced Cholinergic Transmission and Severity of Disease. Vol. 94, Mayo Clinic Proceedings. Elsevier Ltd; 2019. p. 757–62. Durga J, Van Boxtel MPJ, Schouten G, Kok FJ, Jolles J, Katan MB, et al. Articles Eff ect of 3-year folic acid supplementation on cognitive function in older adults in the 20 FACIT trial: a randomised, double blind, controlled trial [Internet]. Vol. 369, www.thelancet.com. 2007. Available from: www.thelancet.com Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr. 2007 Jan 1;85(1):193–200. Genoud S, Senior AM, Hare DJ, Double KL. Meta-Analysis of Copper and Iron in Parkinson’s Disease Brain and Biofluids. Movement Disorders. 2020 Apr 1;35(4):662–71. Adani G, Filippini T, Michalke B, Vinceti M. Selenium and Other Trace Elements in the Etiology of Parkinson’s Disease: A Systematic Review and Meta-Analysis of Case-Control Studies. Vol. 54, Neuroepidemiology. S. Karger AG; 2020. p. 1–23. Xue W, You J, Su Y, Wang Q. The Effect of Magnesium Deficiency on Neurological Disorders: A Narrative Review Article [Internet]. Vol. 48, Iran J Public Health. 2019. Available from: http://ijph.tums.ac.ir Barnham KJ, Bush AI. Metals in Alzheimer’s and Parkinson’s Diseases. Curr Opin Chem Biol. 2008 Apr 1;12(2):222–8. Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, et al. Dietary intake of metals and risk of Parkinson’s disease: A case-control study in Japan. J Neurol Sci. 2011 Jul 15;306(1–2):98–102. Barichella M, Cereda E, Cassani E, Pinelli G, Iorio L, Ferri V, et al. Dietary habits and neurological features of Parkinson’s disease patients: Implications for practice. Clinical Nutrition. 2017 Aug 1;36(4):1054–61. Álvarez-Calatayud G, Guarner F, Requena T, Marcos A. Diet and microbiota. Impact on health. Nutr Hosp. 2018 Sep 1;35(Ext6):11–5. Zhang X, Tang B, Guo J. Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies. Vol. 12, Translational Neurodegeneration. BioMed Central Ltd; 2023. Jesús Martínez-Tapia R, Estrada-Rojo F, Alejandro Hernández-Chávez A, Barajas- Martínez A, Islas Escoto S, Navarro L, et al. Neuroinflamación: el ying-yang de la neuroinmunología.
dc.rights.uri.spa.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.license.spa.fl_str_mv	Atribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	http://creativecommons.org/licenses/by-nc-nd/2.5/co/ Atribución-NoComercial-SinDerivadas 2.5 Colombia http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.spa.fl_str_mv	PDF
dc.coverage.spatial.spa.fl_str_mv	Pereira
institution	Universidad Libre
bitstream.url.fl_str_mv	http://repository.unilibre.edu.co/bitstream/10901/30379/4/ARTICULO_DE_REVISION_Analisis_de_la_investigacion_de_los_nutrientes_neuroprotectores_en_el_paciente_con_EP-2.pdf.jpg http://repository.unilibre.edu.co/bitstream/10901/30379/3/license.txt http://repository.unilibre.edu.co/bitstream/10901/30379/1/ARTICULO_DE_REVISION_Analisis_de_la_investigacion_de_los_nutrientes_neuroprotectores_en_el_paciente_con_EP-2.pdf http://repository.unilibre.edu.co/bitstream/10901/30379/2/formato%20AUTORIZACION%20Biblioteca%201.docx
bitstream.checksum.fl_str_mv	caea952e10fd66567d79fed682ce96ab 8a4605be74aa9ea9d79846c1fba20a33 ba69ba7ed10b2041a0abfe6b5390b549 25faac466e7337b88a8b2f93fa85d393
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional Unilibre
repository.mail.fl_str_mv	repositorio@unilibrebog.edu.co
_version_	1831929211787411456
spelling	Buritica, Hector MarioVásquez Sánchez, María PaulaTrujillo Tobón, SarahPereira2024-12-04T17:12:50Z2024-12-04T17:12:50Z2024-11-29https://hdl.handle.net/10901/30379La enfermedad de Parkinson (EP), es uno de los trastornos neurodegenerativos más prevalentes a nivel mundial, afectando aproximadamente a 10 millones de personas. (1) La investigación sobre nutrientes neuroprotectores, ha emergido como un área prometedora para el desarrollo de intervenciones dietéticas, que podrían modificar el curso de la enfermedad. El objetivo de esta revisión fue, analizar los avances recientes en la investigación sobre nutrientes neuroprotectores en la enfermedad de Parkinson. Evaluando el potencial neuroprotectora como estrategias terapéuticas complementarias, se realizó una revisión bibliográfica siguiendo las directrices PRISMA (Preferred Reporting Items For Systematic Reviews and Meta-Analyses) consultando las bases de datos electrónicas PubMed, Scielo, Scopus, Dialnet, Science Direct y Google académico. Se incluyó estudios científicos, revisiones sistemáticas, ensayos clínicos aleatorizados y estudios de cohorte que evaluaran específicamente nutrientes con factor neuroprotector en la enfermedad de Parkinson. La vitamina E, el ácido docosahexaenoico (DHA), la coenzima Q10, los polifenoles y flavonoides demostraron modular vías inflamatorias y disminución de la α-sinucleina demostrando resultados prometedores; la evidencia actual sugiere un papel prometedor de los nutrientes neuroprotectores en la enfermedad de Parkinson, aunque se requiere mayor investigación para traducir estos hallazgos en intervenciones clínicas efectivas se destacan determinadas estrategias nutricionales personalizadas así como la intervención dietoterapéutica considerando factores genéticos, ambientales y el estadio de la enfermedad.Universidad Libre Seccional Pereira -- Facultad de Ciencias de la Salud, Exactas y Naturales -- Nutrición y DietéticaParkinson's disease (PD), is one of the most prevalent degenerative disorders worldwide, affecting approximately 10 million people.(1) Research on neuroprotective nutrients has emerged as a promising area for the development of dietary interventions that could modify the course of the disease. Recent advances in research evaluating neuroprotective potential as complementary therapeutic strategies were analyzed, a literature review was conducted following PRISMA guidelines by consulting the electronic databases PubMed, Scielo, Scopus, Dialnet, Science Direct and Google Scholar. We included scientific studies, systematic reviews, randomized clinical trials and cohort studies that specifically evaluated nutrients with a neuroprotective factor in Parkinson's disease. Vitamin E, docosahexaenoic acid (DHA), coenzyme Q10, polyphenols and flavonoids were shown to modulate inflammatory pathways and decrease α-synuclein showing promising results; current evidence suggests a promising role of neuroprotective nutrients in Parkinson's disease, although further research is required to translate these findings into effective clinical interventions certain personalized nutritional strategies as well as dietary therapeutic intervention considering genetic, environmental and disease stage factors are highlighted.PDFhttp://creativecommons.org/licenses/by-nc-nd/2.5/co/Atribución-NoComercial-SinDerivadas 2.5 Colombiainfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Enfermedad de ParkinsonNutrientesNeuroprotectoresAntiinflamatoriosParkinson's diseaseNutrientsNeuroprotectiveAnti-inflammatory AgentsAnálisis en la investigación de los nutrientes neuroprotectores, en el paciente con enfermedad de Parkinson (EP).Analysis in the investigation of neuroprotective nutrients in the Parkinson's disease patientTesis de Pregradoinfo:eu-repo/semantics/bachelorThesishttp://purl.org/coar/resource_type/c_7a1fSaavedra Moreno JS, Millán PA, Buriticá Henao OF. Introducción, epidemiología y diagnóstico de la enfermedad de Parkinson. Acta Neurológica Colombiana. 2019 Sep 1;35(3 Supl 1):2–10.Saavedra Moreno JS, Millán PA, Buriticá Henao OF. Introducción, epidemiología y diagnóstico de la enfermedad de Parkinson. Acta Neurológica Colombiana. 2019 Sep 1;35(3 Supl 1):2–10.Muentes Solorzano JM, Lucas Quijije JK, Menéndez Pin T del R, Cornejo Vera JV. Causas y efectos de los pacientes diagnosticados con el mal de Parkinson. RECIMUNDO. 2020 Oct 15;4(4):496–508.Ospina-García N. Trastornos del sueño y dolor en la enfermedad de Parkinson. Acta Neurológica Colombiana. 2019 Sep 1;35(3 Supl 1):63–8.Rodríguez-Carrillo JC, Ibarra M. Depresión y otros trastornos afectivos en la enfermedad de Parkinson. Acta Neurológica Colombiana. 2019 Sep 1;35(3 Supl 1):53–62.Erro R, Brigo F, Tamburin S, Zamboni M, Antonini A, Tinazzi M. Nutritional habits, risk, and progression of Parkinson disease. Vol. 265, Journal of Neurology. Dr. Dietrich Steinkopff Verlag GmbH and Co. KG; 2018. p. 12–23.María A, Periñán T, Directores T, Mir P, María Del Pilar Gómez R, Universidad G, et al. Estudio de factores genéticos y otros marcadores moleculares en la enfermedad de Parkinson Tesis Doctoral.Sienes Bailo P, Llorente Martín E, Calmarza P, Montolio Breva S, Bravo Gómez A, Pozo Giráldez A, et al. Implicación del estrés oxidativo en las enfermedades neurodegenerativas y posibles terapias antioxidantes. Advances in Laboratory Medicine. 2022 Dec 1;3(4):351–60.Tresserra MP, Pineda S. Nutrición y enfermedades neurodegenerativas [Internet]. 2020 [cited 2024 Nov 15]. Available from: https://openaccess.uoc.edu/bitstream/10609/150123/4/NutricionYEnfermedadesNeur odegenerativas.pdfMartínez-Boo N. The role of dietary habits in Parkinson’s disease signs and symptoms: a systematic review. Revista Cientifica de la Sociedad Espanola de Enfermeria Neurologica. 2021 Jul 1;54:30–7.Navajas J. Efectos de la Dieta Mediterránea en la enfermedad de Parkinson [Internet]. 2023 [cited 2024 Nov 15]. Available from: https://uvadoc.uva.es/bitstream/handle/10324/61311/TFG-M-N3094.pdf?sequence=1Quezada Rivera RA, Bonilla Rodríguez FE, Benavides Romero MA, Peña Martínez SL. Alteraciones genéticas asociadas a enfermedad de Parkinson y Alzheimer: evolución y respuesta al tratamiento. Alerta, Revista científica del Instituto Nacional de Salud. 2024 Jan 25;7(1):79–87.Vallejo Zambrano CR, Jiménez Jiménez RA, Morán Rodríguez VE, Gómez Chumo ME, Del Valle Pilay MB, Palma Moreno NJ. Síndrome de Parkinson: Revisión bibliográfica y actualización. RECIMUNDO. 2020 Oct 15;4(4):270–81.Martínez Raull, Gasca C, Sánchez Á, Angel. Jose. Actualización en la enfermedad de Parkinson. 2020;363–79.Cófreces P, Ofman SD, Estay JA, Hermida PD. Enfermedad de Parkinson: una actualización bibliográfica de los aspectos psicosociales. Rev Fac Cienc Med Cordoba. 2022 Jun 6;79(2):181–7.Telarović S. Epidemiology of Parkinson’s Disease. Vol. 59, Archives of psychiatry research. Dr. Mladen Stojanovic University Hospital; 2023. p. 147–8.Estrada I, Martínez H. DIagnóstico y tratamiento de la enfermedad de Parkinson. 8:7.Miranda M, Kuljis R. Transtornos del sueño en las enfermedades neurodegenerativas. 2013 [cited 2024 Nov 15];452–62. Available from: https://www.elsevier.es/es-revista- revista-medica-clinica-las-condes-202-articulo-trastornos-del-sueno-enfermedades- neurodegenerativas- S0716864013701810#:~:text=Los%20trastornos%20del%20sue%C3%B1o%20son, por%20lo%20tanto%20no%20mitigadoGushiken G. RESONANCIA MAGNÉTICA PARA DIAGNÓSTICO PARKINSON EN ETAPA TEMPRANA. Universidad San Martin de Porras; 2021.Alvarez L, Sánchez C, AlvareZ E. SPECT en la enfermedad del Parkinson y otros trastornos del movimiento. Revista Mexicana de neurociencia. 2001;169–75.Zorro-Guío ÓF, Ardila-Martínez MA, Bedoya-Gómez Á, Restrepo HF, Mosquera- Sinisterra JE, Páez C, et al. Deep brain stimulation for Parkinson’s disease: experience, 17 benefits and limitations in a center in Latin America. Cirugia y Cirujanos (English Edition). 2024 May 1;92(3):362–8.Arbelo J, López J, Durán M, Linazasoro G. Guías diagnósticas y terpéuticas de la Sociedad Española de Neurologia [Internet]. 2016 [cited 2024 Nov 16]. Available from: https://www.sen.es/pdf/guias/Guia_oficial_de_practica_clinica_en_la_enfermedad_d e_Parkinson_2016.pdfRodríguez-Violante M, Cervantes-Arriaga A. julio-septiembre 2014 \| 157 Fabián Dolores-Velasco, et al Arch Neurocien (Mex) INNN. Vol. 19, Arch Neurocien (Mex). 2014.Cabello González C, Trandafir PC. The study of health-related quality of life using PDQ39 in patients with Parkinson’s disease treated with advanced therapies. Revista Cientifica de la Sociedad Espanola de Enfermeria Neurologica. 2018 Jul 1;48:9–14.Bouça-Machado R, Fernandes A, Ranzato C, Beneby D, Nzwalo H, Ferreira JJ. Measurement tools to assess activities of daily living in patients with Parkinson’s disease: A systematic review. Vol. 16, Frontiers in Neuroscience. Frontiers Media S.A.; 2022.Garrido Robres JA, García Ballesteros JG, Martín Villuendas AB. Exploración neurológica y atención primaria. Bloque II: motilidad voluntaria, funciones corticales superiores y movimientos anómalos. Semergen. 2011 Oct;37(8):418–25.Berganzo K, Tijero B, González-Eizaguirre A, Somme J, Lezcano E, Gabilondo I, et al. Síntomas no motores y motores en la enfermedad de Parkinson y su relación con la calidad de vida y los distintos subgrupos clínicos. Neurologia. 2016 Nov 1;31(9):585– 91.Icer MA, Arslan N, Gezmen-Karadag M. Effects of vitamin e on neurodegenerative diseases: An update. Acta Neurobiol Exp (Wars). 2021;81(1):21–33.Chang MC, Kwak SG, Kwak S. Effect of dietary vitamins C and E on the risk of Parkinson’s disease: A meta-analysis. Clinical Nutrition. 2021 Jun 1;40(6):3922–30.Mantle D, Heaton RA, Hargreaves IP. Coenzyme Q10, Ageing and the Nervous System: An Overview. 2021; Available from: https://doi.org/10.3390/antiox11010002Espino Y Sosa S, Reyes-Muñoz E, García-Jiménez G, Martínez-Ruiz A, Cristo- Aguirre MS, Adame-Pinacho R, et al. Impact of omega-3 fatty acid during pregnancy and risk reduction for preterm delivery. Gac Med Mex. 2020;156:S37–42.Van Duynhoven J, Vaughan EE, Jacobs DM, Kemperman RA, Van Velzen EJJ, Gross G, et al. Metabolic fate of polyphenols in the human superorganism. Proc Natl Acad Sci U S A. 2011 Mar 15;108(SUPPL. 1):4531–8.Khan Nova N, Sultana S, Akther R, Ahsan Habib M. Correlation of serum zinc and magnesium with reduced heart rate variability in male Parkinson’s disease patients. Available from: https://doi.org/10.3329/jbsp.Lloret A, Esteve D, Monllor P, Cervera-Ferri A, Lloret A. The effectiveness of vitamin E treatment in alzheimer’s disease. Vol. 20, International Journal of Molecular Sciences. MDPI AG; 2019.Stover PJ. Physiology of Folate and Vitamin B<SUB>12</SUB> in Health and Disease. Nutr Rev. 2006 Mar 23;62(6):3–12.Christine CW, Auinger P, Joslin A, Yelpaala Y, Green R. Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson’s Disease. Movement Disorders. 2018 May 1;33(5):762–70.Heo JH, Hyon-Lee, Lee KM. The possible role of antioxidant vitamin C in Alzheimer’s disease treatment and prevention. Vol. 28, American Journal of Alzheimer’s Disease and other Dementias. SAGE Publications Inc.; 2013. p. 120–5.Smith AD, Refsum H. Homocysteine, B Vitamins, and Cognitive Impairment. Vol. 36, Annual Review of Nutrition. Annual Reviews Inc.; 2016. p. 211–39.Gillies N, Cameron-Smith D, Pundir S, Wall CR, Milan AM. Exploring trajectories in dietary adequacy of the B vitamins folate, riboflavin, vitamins B 6 and B 12, with advancing older age: A systematic review. Vol. 126, British Journal of Nutrition. Cambridge University Press; 2021. p. 449–59.Salazar K, Jara N, Ramírez E, de Lima I, Smith-Ghigliotto J, Muñoz V, et al. Role of vitamin C and SVCT2 in neurogenesis. Vol. 17, Frontiers in Neuroscience. Frontiers Media SA; 2023.Jamali B, Entezari M, Babaei N, Hashemi M. The Evaluation of Vitamin E and TiO2 Nanoparticles Administration in Parkinson’s Rat Model. Cell J. 2023 Feb 1;25(2):102–9.Hao X, Li H, Li Q, Gao D, Wang X, Wu C, et al. Dietary vitamin E intake and risk of Parkinson’s disease: a cross-sectional study. Front Nutr. 2023;10.Taghizadeh M, Tamtaji OR, Dadgostar E, Daneshvar Kakhaki R, Bahmani F, Abolhassani J, et al. The effects of omega-3 fatty acids and vitamin E co- supplementation on clinical and metabolic status in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Neurochem Int. 2017 Sep 1;108:183–9.Olesen RH, Hyde TM, Kleinman JE, Smidt K, Rungby J, Larsen A. Obesity and age- related alterations in the gene expression of zinc-transporter proteins in the human brain. Transl Psychiatry. 2016;6(6).Sikora J, Ouagazzal AM. Synaptic zinc: An emerging player in Parkinson’s disease. Vol. 22, International Journal of Molecular Sciences. MDPI; 2021.Fan YG, Wu TY, Zhao LX, Jia RJ, Ren H, Hou WJ, et al. From zinc homeostasis to disease progression: Unveiling the neurodegenerative puzzle. Pharmacol Res. 2024 Jan 1;199:107039.Lee J, Park S, Jang W. Serum zinc deficiency could be associated with dementia conversion in Parkinson’s disease. Front Aging Neurosci. 2023;15.Vink Robert, Nechifor Mihai. Magnesium in the Central Nervous System. Cambridge University Press; 2012.Kirkland AE, Sarlo GL, Holton KF. The role of magnesium in neurological disorders. Vol. 10, Nutrients. MDPI AG; 2018.Yamanaka R, Shindo Y, Oka K. Magnesium is a key player in neuronal maturation and neuropathology. Int J Mol Sci. 2019 Jul 2;20(14).Huang J, May JM. Ascorbic acid protects SH-SY5Y neuroblastoma cells from apoptosis and death induced by β-amyloid. Brain Res. 2006 Jun 30;1097(1):52–8.Ascorbate-regulation-and-its-neuroprotective-role-.Ballaz S, Morales I, Rodríguez M, Obeso JA. Ascorbate prevents cell death from prolonged exposure to glutamate in an in vitro model of human dopaminergic neurons. J Neurosci Res. 2013 Dec;91(12):1609–17.Shults CW, Oakes D, Kieburtz K, Flint Beal ; M, Haas ; Richard, Juncos JL, et al. Effects of Coenzyme Q 10 in Early Parkinson Disease Evidence of Slowing of the Functional Decline.Cardoso HD, Santos Junior EF Dos, De Santana DF, Gonçalves-Pimentel C, Angelim MK, Isaac AR, et al. Omega-3 deficiency and neurodegeneration in the substantia nigra: Involvement of increased nitric oxide production and reduced BDNF expression. Biochimica et Biophysica Acta (BBA) - General Subjects. 2014 Jun 1;1840(6):1902–12.Valente M, Dentoni M, Bellizzi F, Kuris F, Gigli GL. Specialized Pro-Resolving Mediators in Neuroinflammation: Overview of Studies and Perspectives of Clinical Applications. Vol. 27, Molecules. MDPI; 2022.Yakunin E, Loeb V, Kisos H, Biala Y, Yehuda S, Yaari Y, et al. α-Synuclein neuropathology is controlled by nuclear hormone receptors and enhanced by docosahexaenoic acid in a mouse model for Parkinson’s disease. Brain Pathology. 2012 May;22(3):280–94.Zhang M, Wang S, Mao L, Leak RK, Shi Y, Zhang W, et al. Omega-3 fatty acids protect the brain against ischemic injury by activating Nrf2 and upregulating heme oxygenase 1. Journal of Neuroscience. 2014;34(5):1903–15.Bousquet M, Saint‐Pierre M, Julien C, Salem N, Cicchetti F, Calon F. Beneficial effects of dietary omega‐3 polyunsaturated fatty acid on toxin‐induced neuronal degeneration in an animal model of Parkinson’s disease. The FASEB Journal. 2008 Apr;22(4):1213–25.Nielsen SS, Franklin GM, Longstreth WT, Swanson PD, Checkoway H. Nicotine from edible Solanaceae and risk of Parkinson disease. Ann Neurol. 2013;74(3):472–7.Vauzour D, Rodriguez-Mateos A, Corona G, Oruna-Concha MJ, Spencer JPE. Polyphenols and human health: Prevention of disease and mechanisms of action. Vol. 2, Nutrients. MDPI AG; 2010. p. 1106–31.Williams RJ, Spencer JPE, Rice-Evans C. Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med. 2004 Apr 1;36(7):838–49.Singh NA, Mandal AKA, Khan ZA. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Vol. 15, Nutrition Journal. BioMed Central Ltd.; 2016.Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, et al. ()- Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans [Internet]. 2006. Available from: www.pnas.orgcgidoi10.1073pnas.0510168103Rendeiro C, Rhodes JS, Spencer JPE. The mechanisms of action of flavonoids in the brain: Direct versus indirect effects. Neurochem Int. 2015 Oct 1;89:126–39.Faria A, Mateus N, Calhau C. Flavonoid transport across blood-brain barrier: Implication for their direct neuroprotective actions. Nutrition and Aging. 2012;1(2):89–97.Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by b vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PLoS One. 2010;5(9):1–10.McCarter SJ, Teigen LM, McCarter AR, Benarroch EE, St. Louis EK, Savica R. Low Vitamin B12 and Parkinson Disease: Potential Link to Reduced Cholinergic Transmission and Severity of Disease. Vol. 94, Mayo Clinic Proceedings. Elsevier Ltd; 2019. p. 757–62.Durga J, Van Boxtel MPJ, Schouten G, Kok FJ, Jolles J, Katan MB, et al. Articles Eff ect of 3-year folic acid supplementation on cognitive function in older adults in the 20 FACIT trial: a randomised, double blind, controlled trial [Internet]. Vol. 369, www.thelancet.com. 2007. Available from: www.thelancet.comMorris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr. 2007 Jan 1;85(1):193–200.Genoud S, Senior AM, Hare DJ, Double KL. Meta-Analysis of Copper and Iron in Parkinson’s Disease Brain and Biofluids. Movement Disorders. 2020 Apr 1;35(4):662–71.Adani G, Filippini T, Michalke B, Vinceti M. Selenium and Other Trace Elements in the Etiology of Parkinson’s Disease: A Systematic Review and Meta-Analysis of Case-Control Studies. Vol. 54, Neuroepidemiology. S. Karger AG; 2020. p. 1–23.Xue W, You J, Su Y, Wang Q. The Effect of Magnesium Deficiency on Neurological Disorders: A Narrative Review Article [Internet]. Vol. 48, Iran J Public Health. 2019. Available from: http://ijph.tums.ac.irBarnham KJ, Bush AI. Metals in Alzheimer’s and Parkinson’s Diseases. Curr Opin Chem Biol. 2008 Apr 1;12(2):222–8.Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, et al. Dietary intake of metals and risk of Parkinson’s disease: A case-control study in Japan. J Neurol Sci. 2011 Jul 15;306(1–2):98–102.Barichella M, Cereda E, Cassani E, Pinelli G, Iorio L, Ferri V, et al. Dietary habits and neurological features of Parkinson’s disease patients: Implications for practice. Clinical Nutrition. 2017 Aug 1;36(4):1054–61.Álvarez-Calatayud G, Guarner F, Requena T, Marcos A. Diet and microbiota. Impact on health. Nutr Hosp. 2018 Sep 1;35(Ext6):11–5.Zhang X, Tang B, Guo J. Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies. Vol. 12, Translational Neurodegeneration. BioMed Central Ltd; 2023.Jesús Martínez-Tapia R, Estrada-Rojo F, Alejandro Hernández-Chávez A, Barajas- Martínez A, Islas Escoto S, Navarro L, et al. Neuroinflamación: el ying-yang de la neuroinmunología.THUMBNAILARTICULO_DE_REVISION_Analisis_de_la_investigacion_de_los_nutrientes_neuroprotectores_en_el_paciente_con_EP-2.pdf.jpgARTICULO_DE_REVISION_Analisis_de_la_investigacion_de_los_nutrientes_neuroprotectores_en_el_paciente_con_EP-2.pdf.jpgIM Thumbnailimage/jpeg22942http://repository.unilibre.edu.co/bitstream/10901/30379/4/ARTICULO_DE_REVISION_Analisis_de_la_investigacion_de_los_nutrientes_neuroprotectores_en_el_paciente_con_EP-2.pdf.jpgcaea952e10fd66567d79fed682ce96abMD54LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://repository.unilibre.edu.co/bitstream/10901/30379/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53ORIGINALARTICULO_DE_REVISION_Analisis_de_la_investigacion_de_los_nutrientes_neuroprotectores_en_el_paciente_con_EP-2.pdfARTICULO_DE_REVISION_Analisis_de_la_investigacion_de_los_nutrientes_neuroprotectores_en_el_paciente_con_EP-2.pdfArtículo principalapplication/pdf1099102http://repository.unilibre.edu.co/bitstream/10901/30379/1/ARTICULO_DE_REVISION_Analisis_de_la_investigacion_de_los_nutrientes_neuroprotectores_en_el_paciente_con_EP-2.pdfba69ba7ed10b2041a0abfe6b5390b549MD51formato AUTORIZACION Biblioteca 1.docxformato AUTORIZACION Biblioteca 1.docxapplication/vnd.openxmlformats-officedocument.wordprocessingml.document328456http://repository.unilibre.edu.co/bitstream/10901/30379/2/formato%20AUTORIZACION%20Biblioteca%201.docx25faac466e7337b88a8b2f93fa85d393MD5210901/30379oai:repository.unilibre.edu.co:10901/303792024-12-05 06:00:58.987Repositorio Institucional Unilibrerepositorio@unilibrebog.edu.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

Análisis en la investigación de los nutrientes neuroprotectores, en el paciente con enfermedad de Parkinson (EP).

Publicaciones similares